Non-steroidal anti-inflammatory drugs (NSAIDs)

Support for education and learning: Academic detailing aid

February 2012
This Non-Steroidal anti-inflammatory drugs (NSAID) Academic detailing aid is designed to be used by experience prescribing and medicines management personnel to support discussions with prescribers on the key prescribing and medicines optimisation messages from the ‘NPC Key Therapeutic Topics – medicines management options for local implementation’ document. This academic detailing aid is not NICE guidance.

**Issue date:** 2012

Implementation of NICE guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement NICE guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in NICE guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

---

**National Institute for Health and Clinical Excellence**

MidCity Place, 71 High Holborn, London WC1V 6NA  www.nice.org.uk

© National Institute for Health and Clinical Excellence, 2012. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
Supporting notes for the use of NICE Academic Detailing Aids:

Non-steroidal anti-inflammatory drugs (NSAIDs)

- NICE academic detailing aids (ADA) are designed to be used by experienced prescribing and medicines management personnel to support discussions with prescribers on the key prescribing and medicines optimisation messages from the ‘NPC Key Therapeutic Topics – medicines management options for local implementation’ document (available from www.npc.nhs.uk/qipp/#qipp).

- Before using any NICE ADA, users must familiarise themselves with the content of the relevant QIPP Key Slides and accompanying notes (available to download from www.npc.nhs.uk/qipp/)

- Users are also advised to access the QIPP comparator data on this topic and familiarise themselves with local and national prescribing variations at www.nhsbsa.nhs.uk/PrescriptionServices/3334.aspx

- The principles that support the use of academic detailing to improve clinical decision-making have been documented widely. As far back as 1990, Soumerai and Avorn described how ADAs had been used to reduce inappropriate prescribing as well as unnecessary health care expenditure. The authors highlighted the following techniques as being particularly important to successful academic detailing:
  1. Conducting interviews to investigate baseline knowledge and motivations for current prescribing patterns.
  2. Focusing programmes on specific categories of physicians as well as on their opinion leaders.
  3. Defining clear educational and behavioural objectives.
  4. Establishing credibility through a respected organisational identity, referencing authoritative and unbiased sources of information, and presenting both sides of controversial issues.
  5. Stimulating active physician participation in educational interactions.
  6. Using concise graphic educational materials.
7. Highlighting and repeating the essential messages.
8. Providing positive reinforcement to improved practices in follow-up visits.

- The National Audit Office’s 2007 publication, ‘Influencing Prescribing Cost and Quality – a suggested communication plan for prescribing advisers,’ suggests further ways to increase the impact of communication with clinicians. This includes sections on visiting clinicians, building a relationship, the relationship process, getting agreement, getting your plans adopted, and supporting activities, as well as follow up and monitoring.

Acronyms and symbols used in this ADA include:

**NSAID**: non-steroidal anti-inflammatory drug

**CV**: cardiovascular

**GI**: gastrointestinal

**OA**: osteoarthritis

**PPI**: proton-pump inhibitor

**MI**: myocardial infarction

**MHRA**: Medicines and Healthcare products Regulatory Agency

The black triangle symbol ▼ identifies newly licensed medicines that are monitored intensively by the MHRA. All suspected reactions (including those considered not to be serious) should be reported through the Yellow Card Scheme (www.yellowcard.gov.uk)

References:

1. Soumerai SB. Avorn J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAMA 1990;263:549–56

### Academic detailing aid

**Non-steroidal anti-inflammatory drugs (NSAIDs)**

**Prescribing considerations**

<table>
<thead>
<tr>
<th>What are the issues here?</th>
<th>What would good practice look like?</th>
</tr>
</thead>
<tbody>
<tr>
<td>- There is wide variation in the volume of NSAID prescribing across PCTs in England. Within this, there is considerable variation in the proportional prescribing of diclofenac and other NSAIDs associated with a higher cardiovascular (CV) risk.¹</td>
<td>- Paracetamol and/or topical NSAIDs, should be offered ahead of oral NSAIDs (including coxibs), or opioids, in osteoarthritis.²</td>
</tr>
<tr>
<td>- Despite specific safety concerns associated with its use, the volume of etoricoxib▼ prescribing has remained constant over the last 5 years at around 400,000 items per year within primary care in England.¹</td>
<td>- If an NSAID is clinically necessary, consider <strong>low-dose ibuprofen</strong> (1200 mg/day or less) or <strong>naproxen</strong> (1000 mg/day or less) as first-line options.³</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Why is this important?</th>
<th>What can we do?</th>
</tr>
</thead>
<tbody>
<tr>
<td>- All NSAIDs are associated with CV, GI and renal side effects.³</td>
<td>- Prescribe NSAIDs at the <strong>lowest effective dose</strong> and for the <strong>shortest period of time</strong> to control symptoms.³</td>
</tr>
<tr>
<td>- NSAID treatment can result in hospital admissions for upper GI bleeding, acute renal failure, congestive heart failure and CV events such as stroke and MI.³</td>
<td>- <strong>Review NSAID prescribing</strong> widely and on a routine basis, especially in people at higher risk of GI, renal and CV morbidity and mortality (e.g. older patients).³</td>
</tr>
<tr>
<td>- Coxibs and diclofenac are associated with an increased CV risk compared with low dose (1200 mg/day or less) ibuprofen and naproxen.⁶</td>
<td>- <strong>Review patients who are currently prescribed NSAIDs.</strong> If continued use is necessary, consider changing to low-dose ibuprofen (1200 mg/day or less) or <strong>naproxen</strong> (1000 mg/day).³</td>
</tr>
<tr>
<td>- Etoricoxib▼ is contra-indicated in certain patients with high blood pressure because of its cardiovascular risk profile.⁷</td>
<td>- <strong>Review patients on etoricoxib▼</strong> and ensure prescribing is in line with MHRA and NICE guidance²,⁷</td>
</tr>
</tbody>
</table>

**Note:** The term ‘NSAIDs’ is taken to mean traditional NSAIDs (e.g. diclofenac, naproxen, ibuprofen), etodolac, meloxicam, or coxibs (e.g. celecoxib, etoricoxib)

© National Institute for Health and Clinical Excellence, 2012. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of National Institute for Health and Clinical Excellence, 71 High Holborn, London WC1V 6NA
# Prescribing NSAIDs

**A framework for decision-making**

<table>
<thead>
<tr>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>There is no strong evidence to suggest NSAIDs have a consistent benefit over paracetamol in osteoarthritis (although some patients obtain greater symptom relief from NSAIDs).</em>&lt;sup&gt;2&lt;/sup&gt;</td>
<td><em>There is no good evidence to suggest there are any differences in the GI risk of NSAIDs (coxibs or traditional NSAIDs) when prescribed with a PPI.</em>&lt;sup&gt;3&lt;/sup&gt; Choice of NSAID, when prescribed with a PPI, should be informed by other potential side effects, particularly CV effects.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td><em>All NSAIDs have analgesic effects of similar magnitude&lt;sup&gt;2&lt;/sup&gt; but there is considerable inter-patient variability.</em></td>
<td><em>Diclofenac and coxibs are associated with the highest CV risk, naproxen and low-dose ibuprofen with the lowest CV risk.</em>&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cost</th>
<th>Patient factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Etoricoxib▼ represents around 3% of all NSAIDs prescribed, yet accounts for nearly 13% of the total costs.</em>&lt;sup&gt;1&lt;/sup&gt;</td>
<td><em>All NSAIDS vary in their level of potential toxicity. When prescribing NSAIDs, individual risk factors should be taken into account, and consideration given to appropriate assessment and/or on-going monitoring for these risk factors.</em>&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td><em>Prescribing of etoricoxib▼ accounts for more than £10 million per year of primary care prescribing costs.</em>&lt;sup&gt;1&lt;/sup&gt;</td>
<td><em>Etoricoxib▼ requires extra monitoring for CV side effects, including high blood pressure.</em>&lt;sup&gt;7&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

## References:
1. From data provided by [NHSBSA Prescription Services](http://www.nhsbsa.nhs.uk/)
4. NICE. Rheumatoid arthritis. Full clinical guideline 79. February 2009
5. NICE. Low back pain. Full clinical guideline 88. May 2009
6. MHRA. Safety of selective and non-selective NSAIDs. October 2006
8. NPC. Key therapeutic topics – Medicines management options for local implementation V3. Updated July 2011

The black triangle symbol ▼ identifies newly licensed medicines that are monitored intensively by the MHRA. All suspected reactions (including those considered not to be serious) should be reported through the Yellow Card Scheme (www.yellowcard.gov.uk)
Related NICE guidance